HOXC10基因对脑胶质瘤细胞生物学行为的影响及其在肿瘤微环境中的机制
研究利用TCGA和CGGA数据库分析HOXC10在脑胶质瘤中的表达及与生存的关系,并在U251细胞中通过siRNA敲低HOXC10,检测增殖、迁移、凋亡及趋化因子表达和巨噬细胞招募极化。结果显示HOXC10在高级别胶质瘤中高表达且与不良预后相关,敲低可抑制增殖迁移并促进凋亡,可能通过CCL2招募并极化M2型巨噬细胞发挥免疫抑制作用。
要点
- HOXC10在高级别胶质瘤中表达高于低级别胶质瘤,高表达者5年生存率较低。
- 敲低HOXC10可抑制U251细胞增殖、迁移并促进凋亡。
- HOXC10可能通过促进CCL2表达招募并极化M2型巨噬细胞发挥免疫抑制作用。
核心结论
- HOXC10在脑胶质瘤中高表达且与患者不良预后有关。
- 敲低HOXC10可降低人脑胶质瘤U251细胞的增殖、迁移及转移能力。
- HOXC10在脑胶质瘤微环境中可能通过促进CCL2表达进而招募并极化肿瘤相关巨噬细胞即M2型巨噬细胞发挥免疫抑制作用。
研究设计与样本
- 研究应用TCGA与CGGA数据库分析HOXC10在高级别胶质瘤(胶质母细胞瘤)和低级别胶质瘤中的表达水平及其对患者生存的影响。
- 体外实验将HOXC10-siRNA-1、HOXC10-siRNA-2和siRNA NC转染至U251细胞,并在转染组中加入100 ng/mL重组蛋白趋化因子配体2(reCCL2),记为HOXC10-siRNA-1+reCCL2和HOXC10-siRNA-2+reCCL2组。
主要发现
- TCGA数据库高级别脑胶质瘤中HOXC10中位表达水平为8.51,高于低级别脑胶质瘤的1.00(P<0.001);CGGA数据库高级别脑胶质瘤中HOXC10中位表达水平为0.83,高于低级别脑胶质瘤的0.00(P<0.001)。
- TCGA数据库HOXC10高表达患者5年生存率为28.2%,低于HOXC10低表达者的78.7%(P<0.001);CGGA数据库HOXC10高表达患者5年生存率为20.3%,低于HOXC10低表达者的58.0%(P<0.001)。
- HOXC10-siRNA-1组和HOXC10-siRNA-2组细胞迁移数分别为(45±3)个和(69±4)个,均低于NC组的(159±3)个(均P<0.05);48 h细胞迁移率分别为(15±2)%和(28±4)%,低于NC组的(80±5)%(均P<0.05)。
- HOXC10-siRNA-1组和HOXC10-siRNA-2组96 h吸光度值分别为0.44±0.05和0.32±0.02,低于NC组的0.92±0.12(均P<0.05);凋亡率分别为(10.23±1.24)%和(13.81±2.16)%,高于NC组的(4.60±0.07)%(均P<0.05)。
- HOXC10-siRNA-1组和HOXC10-siRNA-2组U251细胞中CCL2表达水平分别为271.63±44.27和371.66±50.21,低于NC组的933.93±29.84(均P<0.05);CCL5、CXCL10、CXCL11表达水平均高于NC组(均P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the effects of Homeobox C10 (HOXC10) on biological characteristics such as migration, invasion and proliferation of glioma cancer cells and to explore the role of HOXC10 gene in glioma microenvironment. Methods: The expression level of HOXC10 in high grade glioma (glioblastoma) and low grade glioma and its effect on patient survival were analyzed by using The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) database. Hoxc10-siRNA-1, HOXC10-siRNA-2 and siRNA negative control (NC) were transfected into U251 cells according to the operation instructions of HOXC10-siRNA transfection. 100 ng/ mL recombinant protein chemokine ligand 2 (reCCL2) was added into the transfection group, and was labeled as HOXC10-siRNA-1+ reCCL2 and HOXC10-siRNA-2+ reCCL2 groups. The expressions of HOXC10 mRNA and target protein in each group was detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) and western blot. The proliferation ability of cells in each group was detected by cell counting kit 8 (CCK8) method. The migration ability of cells was detected by Transwell assay and Nick assay, and cell apoptosis was detected by flow cytometry. The expression of chemokines in each group was detected by multiple factors. Co-incubation assays were performed to determine the role of HOXC10 and chemokine ligand 2 (CCL2) in recruiting and polarizing tumor-associated macrophages (M2-type macrophages). Results: The median expression level of HOXC10 in high grade gliomas was 8.51, higher than 1.00 in low grade gliomas (P<0.001) in TCGA database. The median expression level of HOXC10 in high grade gliomas was 0.83, higher than 0.00 in low grade gliomas (P=0.002) in CGGA database. The 5-year survival rate of patients with high HOXC10 expression in TCGA database was 28.2%, lower than 78.7% of those with low HOXC10 expression (P<0.001), and the 5-year survival rate of patients with high HOXC10 expression in CGGA database was 20.3%, lower than 58.0% of those with low HOXC10 expression (P<0.001). The numbers of cell migration in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (45±3) and (69±4) respectively, lower than (159±3) in NC group (P<0.05). The cell mobility of HOXC10-siRNA-1 group and HOXC10-siRNA-2 group at 48 hours were (15±2)% and (28±4)% respectively, lower than (80±5)% of NC group (P<0.05). The expressions of vimentin in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (141 740.00±34 024.56) and (94 655.00±5 687.97), N-cadherin were (76 810.00±14.14) and (94 254.00±701.45), β-catenin were (75 786.50±789.84) and (107 296.50±9 614.53), lower than (233 768.50±34 114.37), (237 154.50±24 715.50) and (192 449.50±24 178.10) of NC group (P<0.05). The A value of HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (0.44±0.05) and (0.32±0.02) at 96 hours, lower than 0.92±0.12 of NC group (P<0.05). The apoptosis rates of HOXC10-siRNA-1 group and HOXC10 siRNA-2 group were (10.23±1.24)% and (13.81±2.16)%, higher than (4.60±0.07)% of NC group (P<0.05). The expression levels of CCL2 in U251 cells in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were (271.63±44.27) and (371.66±50.21), lower than (933.93±29.84) in NC group (P<0.05). The expression levels of CCL5 (234.81±5.95 and 232.62±5.72), CXCL10 (544.13±48.14 and 500.87±15.65) and CXCL11 (215.75±15.30 and 176.18±16.49) in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were higher than those in NC group (9.98±0.71, 470.54±18.84 and 13.55±0.73, respectively, P<0.05). The recruited numbers of CD14(+) THP1 in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were (159.33±1.15) and (170.67±1.15), respectively, lower than (360.00±7.81) in NC group (P<0.05), while addition of reCCL2 promoted the recruitment of CD14(+) THP1 cells (287.00±3.61 and 280.67±2.31 in HOXC10-siRNA-1+ reCCL2 group and HOXC10-siRNA-2+ reCCL2 group, respectively, P<0.05). The expressions level of M2-type macrophage-related gene TGF-β in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (0.30±0.02) and (0.28±0.02), respectively, lower than (1.06±0.10) in NC group (P<0.05). The expressions level of M1-related gene NOS2 in HOXC10-siRNA-1 and HOXC10-siRNA-2 were (11 413.95±1 911.85) and (5 894.00±945.21), respectively, higher than (13.39±4.32) in NC group (P<0.05). Conclusions: The expression of HOXC10 in glioma is high and positively correlated with the poor prognosis of glioma patients. Knockdown of HOXC10 can inhibit the proliferation, migration and metastasis of human glioma U251 cells. HOXC10 may play an immunosuppressive role in glioma microenvironment by promoting the expression of CCL2 and recruiting and polarizing tumor-associated macrophages (M2 macrophages). 目的: 探讨同源盒基因C10(HOXC10)对脑胶质瘤细胞生物学行为的影响及其在肿瘤微环境中的作用机制。 方法: 应用癌症基因组图谱(TCGA)与中国脑胶质瘤基因组图谱(CGGA)数据库分析HOXC10在高级别胶质瘤(胶质母细胞瘤)和低级别胶质瘤中的表达水平及其对患者生存的影响。按照HOXC10-siRNA转染操作说明书分别将HOXC10-siRNA 1(HOXC10-siRNA 1组)、HOXC10-siRNA 2(HOXC10-siRNA 2组)和siRNA NC(NC组)转染至U251细胞,在转染组中分别加入100 ng/ml重组蛋白趋化因子配体2(reCCL2),记为HOXC10-siRNA 1+reCCL2和HOXC10-siRNA 2+reCCL2组。采用实时荧光定量聚合酶链反应和Western blot法检测各组细胞中HOXC10 mRNA和目的蛋白的表达,细胞计数试剂盒8法检测各组细胞的增殖能力,Transwell实验和划痕实验检测细胞迁移能力,流式细胞术检测细胞凋亡情况,多因子检测各组细胞中趋化因子的表达。共孵育实验检测HOXC10和趋化因子配体2(CCL2)招募并极化肿瘤相关巨噬细胞(M2型巨噬细胞)的作用。 结果: TCGA数据库高级别脑胶质瘤中HOXC10中位表达水平(8.51)高于低级别脑胶质瘤(1.00,P<0.001),CGGA数据库高级别脑胶质瘤中HOXC10中位表达水平(0.83)高于低级别脑胶质瘤(0.00, P<0.001)。TCGA数据库HOXC10高表达患者5年生存率(28.2%)低于HOXC10低表达者(78.7%,P<0.001),CGGA数据库HOXC10高表达患者5年生存率(20.3%)低于HOXC10低表达者(58.0%, P<0.001)。HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞迁移数[分别为(45±3)个和(69±4)个]均低于NC组[(159±3)个,均P<0.05]。HOXC10-siRNA 1组和HOXC10-siRNA 2组48 h细胞迁移率[分别为(15±2)%和(28±4)%]低于NC组[(80±5)%,均P<0.05]。HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞中Vimentin的表达水平分别为141 740.00±34 024.56和94 655.00±5 687.97,N-cadherin的表达水平分别为76 810.00±14.14和94 254.00±701.45,β-catenin的表达水平分别为75 786.50±789.84和107 296.50±9 614.53,均低于与NC组(分别为233 768.50±34 114.37、237 154.50±24 715.50和192 449.50±24 178.10,均P<0.05)。HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞(96 h)吸光度值(分别为0.44±0.05和0.32±0.02)低于NC组(0.92±0.12,均P<0.05),HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞凋亡率[分别为(10.23±1.24)%和(13.81±2.16)%]高于NC组[(4.60±0.07)%,均P<0.05]。HOXC10-siRNA 1组和HOXC10-siRNA 2组U251细胞中CCL2的表达水平分别为271.63±44.27和371.66±50.21,低于NC组(933.93±29.84,均P<0.05),CCL5(分别为234.81±5.95和232.62±5.72)、CXCL10(分别为544.13±48.14和500.87±15.65)、CXCL11的表达水平(分别为215.75±15.30和176.18 ±16.49)均高于NC组(分别为9.98±0.71、470.54±18.84和13.55±0.73,均P<0.05)。HOXC10-siRNA 1组和HOXC10-siRNA 2组招募CD14(+) THP1细胞数分别为(159.33±1.15)个和(170.67±1.15)个,低于NC组[(360.00±7.81)个,均P<0.05];HOXC10-siRNA 1组和HOXC10-siRNA 2组招募CD14(+) THP1细胞数分别为(159.33±1.15)个和(170.67±1.15)个,低于HOXC10-siRNA 1+reCCL2组和HOXC10-siRNA 2+reCCL2组[分别为(287.00±3.61)个和(280.67±2.31)个,均P<0.05]。HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞中肿瘤生长因子β表达水平(分别为0.30±0.02和0.28±0.02)低于NC组(1.06±0.10,均P<0.05),HOXC10-siRNA 1组和HOXC10-siRNA 2组细胞中NOS2表达水平(分别为11 413.95±1 911.85和5 894±945.21)高于NC组(13.39±4.32,均P<0.05)。 结论: HOXC10在脑胶质瘤中高表达,且与脑胶质瘤患者不良预后有关。敲低HOXC10的表达可降低人脑胶质瘤U251细胞的增殖、迁移及转移能力。HOXC10在脑胶质瘤微环境中可能通过促进CCL2的表达进而招募并极化肿瘤相关巨噬细胞即M2型巨噬细胞从而发挥免疫抑制的作用。.
引用
- Jiang WY, Lei QY, Liu SS, et al. [The effect of HOXC10 gene on biological behaviors of glioma cells and mechanism in tumor microenvironment]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35316872. doi:10.3760/cma.j.cn112152-20200326-00266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。